Carl Dambkowski, Director at Oruka Therapeutics, Inc. (ORKA), sold 105,000 shares at $58.43 ($6.2M) on 2026-05-21, disclosed to the SEC on 2026-05-22.
Scheduled sale ($6.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $58.43 | 38,318 | $2.2M | 36.2% |
| 2 | $59.10 | 53,447 | $3.2M | 51.0% |
| 3 | $59.97 | 13,235 | $794K | 12.8% |
| Total | $58.97 avg | 105,000 | $6.2M | 100% |
| Filing → |
| ORKA | SELL | 2026-06-12 | $2.5M | — | Filing → |
| APGE | SELL | 2026-06-05 | $433K | — | Filing → |
| APGE | SELL | 2026-05-08 | $463K | — | Filing → |